Tokyo – 9 April 2018, Mr Zhang Boqing, Chairman of Beroni Group and Mr Shigeru Hirabayashi, Chairman of Dendrix. Inc signed an agreement for investment and acquisition.
Nowadays, human health issues are attracting extensive attention around the world, causing Biomedicine industry to become a global booming industry. Japan is one of the leading countries that possess technologies for culturing and processing immune cells. The successful completion of due diligence and decision to invest into Dendrix, marks the first global acquisition of Beroni.
Dendrix, which was established in December 2012, provides immune cell culture for treatment against malignant tumors.Especially for DCimmune cell therapy, it has made a significant breakthrough. Dendrix also has high-quality production R&D institutions and service teams in immune cell therapy. By making the investment,Beroni will introduce Dendrix’s advanced technology in immune cell therapy to the China market to improve Beroni’s competitiveness in the precision medicine sector, and accelerate the commercialization of technological achievements.
The investment is a significant milestone in the cooperation between China and Japan in the field of stem cell technology. Beroni Group will work closely with Dendrix in the field of precision medicine, develop DC immune cell therapy, draw on medical expertise in Japan to explore effective immune cell therapies to fight cancer and to provide new treatments for cancer patients.